Results 71 to 80 of about 3,046 (215)

Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM

Circulation
BACKGROUND: In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), VALOR-HCM trial (Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy [URL: https ...
M. Desai, K. Wolski, A. Owens, J. Geske, S. Saberi, Andrew Wang, M. Sherrid, Paul C. Cremer, N. Lakdawala, A. Tower-Rader, D. Fermin, S. Naidu, Nicholas G Smedira, H. Schaff, Zhiqun Gong, Lana Mudarris, K. Lampl, A. Sehnert, Steven E. Nissen   +18 more
semanticscholar   +1 more source

Integrative simulation analysis of myocardial ischaemia–reperfusion injury

The Journal of Physiology, Volume 604, Issue 18, Page 7640-7662, 15 September 2026.
Abstract figure legend A comprehensive mathematical model of ventricular myocyte was developed to gain insights into the mechanisms underlying cardiac ischaemia–reperfusion injury. The model integrates excitation–contraction (E–C) coupling, cytosolic and mitochondrial pH regulation, pH dependence of major E–C coupling components and cellular energy ...
Takao Shimayoshi, Ayako Takeuchi, Satoshi Matsuoka   +2 more
wiley   +1 more source

Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort.

JACC. Heart failure
BACKGROUND Data assessing the long-term safety and efficacy of mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy are needed. OBJECTIVES The authors sought to evaluate interim results from the EXPLORER-Long Term Extension (LTE)
Florian Rader, A. Oręziak, L. Choudhury, S. Saberi, D. Fermin, M. Wheeler, T. Abraham, P. García-Pavía, D. Zwas, A. Masri, A. Owens, S. Hegde, T. Seidler, S. Fox, G. Balaratnam, A. Sehnert, I. Olivotto   +16 more
semanticscholar   +1 more source

Effects of chemical myosin II cross‐bridge inhibitors on eccentric force production in skinned muscle fibres

Experimental Physiology, Volume 111, Issue 7, Page 3337-3356, 1 July 2026.
Abstract Eccentric muscle contractions are essential for locomotion and daily activities. Force during these contractions depends on both cross‐bridge (XB) and non‐cross‐bridge (non‐XB) elements, including titin, with contributions varying by fibre type and contraction velocity.
André Tomalka, Sven Weidner, Christian Rode, Tobias Siebert   +3 more
wiley   +1 more source

Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial.

JAMA cardiology, 2023
Importance There is an unmet need for novel medical therapies before recommending invasive therapies for patients with severely symptomatic obstructive hypertrophic cardiomyopathy (HCM). Mavacamten has been shown to improve left ventricular outflow tract
M. Desai, A. Owens, K. Wolski, J. Geske, S. Saberi, Andrew Wang, M. Sherrid, P. Cremer, N. Lakdawala, A. Tower-Rader, D. Fermin, S. Naidu, N. Smedira, H. Schaff, E. McErlean, Christina Sewell, Lana Mudarris, Zhiqun Gong, K. Lampl, A. Sehnert, S. Nissen   +20 more
semanticscholar   +1 more source

Real-World Experience of Mavacamten for Patients With Obstructive Hypertrophic Cardiomyopathy in South Korea: A Prospective Multi-Center Observational Study

Korean Circulation Journal
Author's summary Mavacamten, a selective allosteric cardiac myosin inhibitor, brought a transformative shift in the therapeutic landscape of obstructive hypertrophic cardiomyopathy (oHCM). Yet, its real-world evidence in Asians is limited.
Jaehyun Lim, Jae Yeong Cho, S. Kwak, C. Park, Jiesuck Park, Hong-Mi Choi, G. Cho, G. Choi, Jihoon Kim, J. Na, Sun Hwa Lee, M. Jung, K. Kim, H. Jung, Sang-Chol Lee, Hyung-Kwan Kim   +15 more
semanticscholar   +1 more source

Metabolite‐sensitive cross‐bridge models of human atria reveal the impact of diabetes on muscle mechanoenergetics

The Journal of Physiology, Volume 604, Issue 13, Page 5316-5341, 1 July 2026.
Abstract figure legend In this study, we used mathematical modelling to explore the effect of diabetes on muscle mechanoenergetics. Our parameterisation of cross‐bridge models using data from non‐diabetic and diabetic human atrial tissues revealed lower values for cross‐bridge stiffness, detachment rates, attachment rates and lower ATP sensitivity in ...
Julia H. Musgrave, June‐Chiew Han, Marie‐Louise Ward, Andrew J. Taberner, Kenneth Tran   +4 more
wiley   +1 more source

Mavacamten in Hypertrophic Cardiomyopathy: Unraveling Therapeutic Potential and Clinical Implications in Advancing Cardiovascular Medicine [PDF]

Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by myocardial hypertrophy, often leading to various cardiovascular symptoms and complications.
Ankit Kumar, Prachi Pandey, Dilip Jangid, Sanjeevani Tyagi, Rahul Raj
core   +1 more source

Consistency and clarity of pharmacogenomic guidance in UK medicine patient information leaflets: A cross‐sectional analysis

British Journal of Clinical Pharmacology, Volume 92, Issue 6, Page 1934-1939, June 2026.
Pharmacogenomic (PGx) information has the potential to support the safe and effective use of medicines, yet there is uncertainty about how this information can be best communicated to patients. Summaries of product characteristics (SmPCs) and patient information leaflets (PILs) for all UK‐approved medicines with strong evidence supporting a PGx ...
Parth Narlawar, Chloe Ratcliffe, Videha Sharma, William G. Newman, Munir Pirmohamed, John McDermott   +5 more
wiley   +1 more source

Mavacamten: Real-World Experience From 22 Months of the Risk Evaluation and Mitigation Strategy (REMS) Program

Circulation: Heart Failure
BACKGROUND: Mavacamten is the only cardiac myosin inhibitor approved by the U.S. Food and Drug Administration for the treatment of patients with symptomatic New York Heart Association class II–III obstructive hypertrophic cardiomyopathy.
M. Desai, Dewey Seto, Michael Cheung, Sonia Afsari, N. Patel, Arnaud Bastien, Jeffrey Lockman, Michele Coiro, Matthew W. Martinez   +8 more
semanticscholar   +1 more source